RT Book, Section
A1 Berger, Carolina
A1 Riddell, Stanley R.
A2 Kaushansky, Kenneth
A2 Lichtman, Marshall A.
A2 Prchal, Josef T.
A2 Levi, Marcel M.
A2 Press, Oliver W.
A2 Burns, Linda J.
A2 Caligiuri, Michael
SR Print(0)
ID 1121090913
T1 Immune Cell Therapy
T2 Williams Hematology, 9e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071833004
LK hemonc.mhmedical.com/content.aspx?aid=1121090913
RD 2024/04/19
AB SUMMARYT  cells  represent  an  important  component  of  the  host  response  to  pathogens  and  tumors.  Adoptive  T-cell  therapy,  in  which  T  cells  are  isolated  or  engineered  to  be  specific  for  molecules  expressed  on  diseased  cells  and  administered  to  patients,  has  shown  efficacy  in  infections  and  malignancy.  Clinical  applications  of  T-cell  therapy  have  been  facilitated  by  identification  of  target  antigens  expressed  by  viruses  and  tumors,  improvement  in  strategies  for  the  isolation  and  genetic  engineering  of  antigen-specific  T  cells  with  intrinsic  qualities  that  enable  their  persistence  in  vivo,  and  recognition  that  transferring  T  cells  into  a  lymphopenic  environment  improves  the  efficiency  of  cell  transfer  and  treatment  efficacy.  Insights  into  the  obstacles  to  routinely  achieving  an  effective  antitumor  response  either  by  T-cell  therapy  or  vaccination  have  been  derived  from  careful  analysis  of  clinical  trials,  and  further  development  of  immune  cell  therapy  combined  with  interventions  that  target  specific  regulatory  or  inhibitory  pathways  that  are  present  in  tumor  microenvironments  and  impede  effective  immunity  represent  promising  areas  for  future  applications.